↓ Skip to main content

Obstacles and opportunities in Chinese pharmaceutical innovation

Overview of attention for article published in Globalization and Health, March 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
80 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Obstacles and opportunities in Chinese pharmaceutical innovation
Published in
Globalization and Health, March 2017
DOI 10.1186/s12992-017-0244-6
Pubmed ID
Authors

Jingyun Ni, Junrui Zhao, Carolina Oi Lam Ung, Yuanjia Hu, Hao Hu, Yitao Wang

Abstract

Global healthcare innovation networks nowadays have expanded beyond developed countries with many developing countries joining the force and becoming important players. China, in particular, has seen a significant increase in the number of innovative firms and research organizations stepping up to the global network in recent years. Nevertheless, the intense Research and Development input has not brought about the expectable output. While China is ascending at a great speed to a leading position worldwide in terms of Research and Development investment, scientific publications and patents, the innovation capabilities in the pharmaceutical sector remain weak. This study discusses the challenges and opportunities for pharmaceutical innovation in China. One hand, academic, industrial, institutional and financial constraints were found to be the major and inevitable barriers hindering the development of drug innovation. On the other hand, unique advantages had been observed which included growing pharmaceutical market, Research and Development funding, distinctive source, and international cooperation. The most important thing for China's pharmaceutical sector to leap forward is to break though innovation barriers and integrate own advantages into global value-chain of healthcare product development.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 80 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 14 18%
Student > Master 14 18%
Student > Bachelor 11 14%
Researcher 9 11%
Student > Doctoral Student 6 8%
Other 10 13%
Unknown 16 20%
Readers by discipline Count As %
Business, Management and Accounting 10 13%
Social Sciences 9 11%
Biochemistry, Genetics and Molecular Biology 8 10%
Pharmacology, Toxicology and Pharmaceutical Science 6 8%
Nursing and Health Professions 6 8%
Other 22 28%
Unknown 19 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 May 2017.
All research outputs
#6,508,380
of 11,369,285 outputs
Outputs from Globalization and Health
#473
of 565 outputs
Outputs of similar age
#128,173
of 263,554 outputs
Outputs of similar age from Globalization and Health
#14
of 17 outputs
Altmetric has tracked 11,369,285 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 565 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.3. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,554 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.